KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40494011无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild-Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study (NCCH1512).J Dermatol已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other。PMID 40503645PMC123156362025-Aug0.45The abstract describes an ancillary analysis of a Phase III randomized trial, but the reported outcomes (disease control rate, acneiform rash severity) are not time-to-event efficacy endpoints. No Kaplan-Meier curves, hazard ratios, or time-to-event data (OS, PFS, etc.) are mentioned.无 KM 图
Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials.Lancet Gastroenterol Hepatol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40505666无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.Br J HaematolPMID 40524338PMC123789602025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.JACC Heart Fail入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40540987无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.AtherosclerosisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40543299无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial.Lancet RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40544861无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.Breast Cancer Res Treat疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40549110无 PMCID2025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.Ann Intern MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40550133无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial.Lancet Respir Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40550238无 PMCID2025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma.Clin Pharmacokinet已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。PMID 40551003PMC122637812025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study.Lancet RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40570879无 PMCID2025-Aug0.95This is a randomized, phase 3 trial with a drug intervention (certolizumab pegol) and reports primary results. However, it is not an oncology study (rheumatoid arthritis) and its primary endpoint is a proportion reaching low disease activity at a fixed timepoint (week 12), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR).无 KM 图
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.DrugsPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40571893无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study.Lancet Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40587991无 PMCID2025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.Gynecol OncolAI 判定该论文不进入自动 KM 提取:The record is explicitly identified as a Phase II randomized controlled trial, not Phase III. The keywords mention 'Phase 3 placebo-controlled trial', but this is inconsistent with the primary metadata (title, publication types) and the study's own conclusion, which recommends against Phase III evaluation.PMID 40592025无 PMCID2025-Aug0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。无 KM 图
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40592026无 PMCID2025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40602204无 PMCID2025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.Int J Gynecol Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40616865无 PMCID2025-Aug0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial.Nat Med已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:森林图/亚组分析图;Extended Data Fig. 1:AI 判定为 other;Extended Data Fig. 2:AI 判定为 other。PMID 40628965PMC123537952025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.J Comp Eff Res入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40637159PMC123085432025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:森林图/亚组分析图;Figure 3:森林图/亚组分析图;Figure 4:非 KM 图。PMID 40639383PMC123038612025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.Clin Drug Investig已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:ROC 图;Fig. 2:ROC 图;Fig. 3:ROC 图。PMID 40650731PMC123075572025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40651490无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40652943无 PMCID2025-Aug0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.Future OncolAI 判定该论文不进入自动 KM 提取:This is a matching-adjusted indirect comparison (MAIC) of two separate trials, not a primary Phase III randomized controlled trial reporting original results.PMID 40654300PMC123302742025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial.Mol Genet Metab入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40663813无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4).Am J Respir Crit Care Med已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:生活质量量表图;Figure 2:森林图/亚组分析图;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 forest plot。PMID 40664229PMC123699552025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.Eur Urol OncolPMID 40675873PMC123703842025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.Lancet Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40680752无 PMCID2025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40680754无 PMCID2025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Safety and effectiveness of the Walk 'n Watch structured, progressive exercise protocol delivered by physical therapists for inpatient stroke rehabilitation in Canada: a phase 3, multisite, pragmatic, stepped-wedge, cluster-randomised controlled trial.Lancet NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40683274无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational study.EBioMedicinePMID 40683772PMC123682902025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40685311无 PMCID2025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2.NEJM EvidPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40693847无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT-EXT Pharmacokinetic Analysis.Clin TransplantPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40704545无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study.Expert Opin Biol TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40708530无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Combined Topical Lidocaine and Tetracaine Cream for Facial Fractional Laser Resurfacing Compared With Its Reference Product in Chinese Adults: A Multicenter, Randomized, Double-Blind Phase 3 Study.J Cosmet Dermatol已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图。PMID 40735955PMC123087822025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO.Eur J Neurol已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。PMID 40755069PMC123192382025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.ESMO OpenPMID 40763412PMC123452552025-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40769684无 PMCID2025-Aug0.90The study is a Phase III randomized trial with a drug-containing intervention and reports original results. However, the primary efficacy endpoint is measurable residual disease negativity, not a time-to-event endpoint such as OS, PFS, DFS, etc., and no Kaplan-Meier or hazard ratio for time-to-event outcomes is reported in the provided abstract. Therefore, it does not meet the time-to-event criterion for inclusion in this Kaplan-Meier digitization cohort.无 KM 图
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.Lancet Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40769686无 PMCID2025-Aug0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
Arterial stiffness moderates the link between NfL and cognition: The IGNITE study.Alzheimers Dement入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40775489PMC123314452025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.ESMO OpenPMID 40795788PMC123617732025-Aug0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Mirikizumab Pharmacokinetics and Exposure-Response in Patients With Moderately-To-Severely Active Crohn's Disease: Results From Two Randomized Studies.Clin Transl Sci已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 multi panel km。PMID 40804779PMC123501812025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression.Curr Med Res OpinPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40953132无 PMCID2025-Aug0.98未发现恶性肿瘤人群证据。无 KM 图
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.BloodPMID 40009500PMC128246672025-Jul-310.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.BloodPMID 40233321PMC128246542025-Jul-310.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.N Engl J Med已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。PMID 40459097PMC132922402025-Jul-310.95The trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original report. However, it is excluded because the primary endpoint is MRD-negative status (a response rate), not a time-to-event efficacy endpoint. No time-to-event endpoint (e.g., OS, PFS) or associated statistics (Kaplan-Meier, HR) are reported in the abstract.无 KM 图
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes.Eur J EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40711996无 PMCID2025-Jul-310.98未发现恶性肿瘤人群证据。无 KM 图
Dexamethasone for 12 weeks for reducing fatigue in patients receiving palliative chemotherapy: A Phase 3, Placebo-Controlled, Randomized Controlled Trial.Support Care CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40739403无 PMCID2025-Jul-310.85The trial meets criteria for oncology, human, randomized, Phase III, original result, and drug intervention, but fails the time-to-event endpoint criterion. The primary and secondary outcomes are patient-reported fatigue and quality-of-life measures (SAFE, FA-12, EORTC QLQ-C30), not time-to-event endpoints like OS, PFS, etc.无 KM 图